Home
About Us
About Us
Board of Directors
Scientific Advisory Board
Management Team
Careers
For Researchers
Paxalisib
EVT801
Collaborating with Kazia
Publications and Presentations
For Partners
Our Current Partners
What We Are Looking For
For Patients
Accessing Kazia Drug Candidates in Clinical Trials
Accessing Kazia Drug Candidates for Compassionate Use
Resources for Patients
For Investors
Press Releases
ASX Announcements
Delisting from ASX
How to convert unlisted shares to ADSs
SEC Filings
Corporate Presentations
Annual Reports
Financial Reports
AGM
Corporate Governance
Shareholder Services
Media Centre
Overview
Video
Coverage
Contact
Contact Us
Subscribe to email alerts
Heading &
Sub-heading can be edited through HQI
Home
>
For Investors
>
ASX Announcements
Press Releases
ASX Announcements
Delisting from ASX
How to convert unlisted shares to ADSs
SEC Filings
Corporate Presentations
Annual Reports
Financial Reports
AGM
Corporate Governance
Shareholder Services
ASX Announcements
Filter by Year:
2023
2022
2021
2020
2019
2018
8-Aug-2022
Notification of cessation of securities - KZA
8-Aug-2022
Interim data from MSKCC study
1-Aug-2022
GBM Agile Update
29-Jul-2022
Quarterly Activities/Appendix 4C Cash Flow Report
29-Jul-2022
Quarterly Activities/Appendix 4C Cash Flow Report
12-Jul-2022
Kazia launches new SAB
8-Jul-2022
Cleansing notice
8-Jul-2022
Application for quotation of securities - KZA
6-Jul-2022
FDA grants RPDD to paxaliaib for AT/RT
30-Jun-2022
Kazia progress update
Previous
1
2
3
4
5
6
7
8
9
10
Next